Fucoïdane

De WikiPhyto
Sauter à la navigation Sauter à la recherche

Nom de la substance

Fucoïdane

Famille moléculaire

Source végétale

Propriétés

  • Propriétés anticoagulantes et antiagrégantes [1], [2], [3]
  • Propriétés antitumorales [4], [5], [6], vis-à-vis de cellules de localisations diverses, prostate [7], poumon [8], colon [9]

Effet thérapeutique

Effets indésirables

  • Ne pas associer avec anticoagulants ou antiagrégants

Bibliographie

  1. Mourão PA, Pereira MS. Searching for alternatives to heparin: sulfated fucans from marine invertebrates. Trends Cardiovasc Med. 1999 Nov;9(8):225-32. PMID 11094330
  2. Mourão PA. Use of sulfated fucans as anticoagulant and antithrombotic agents: future perspectives. Curr Pharm Des. 2004;10(9):967-81. PMID 15078127
  3. Pomin VH, Mourão PA. Structure, biology, evolution, and medical importance of sulfated fucans and galactans. Glycobiology. 2008 Dec;18(12):1016-27. doi: 10.1093/glycob/cwn085. PMID 18796647
  4. Li B, Lu F, Wei X, Zhao R. Fucoidan: structure and bioactivity. Molecules. 2008 Aug 12;13(8):1671-95. PMID 18794778
  5. Ale MT, Mikkelsen JD, Meyer AS. Important determinants for fucoidan bioactivity: a critical review of structure-function relations and extraction methods for fucose-containing sulfated polysaccharides from brown seaweeds. Mar Drugs. 2011;9(10):2106-30. doi: 10.3390/md9102106. PMID 22073012
  6. Senthilkumar K, Kim SK. Anticancer effects of fucoidan. Adv Food Nutr Res. 2014;72:195-213. doi: 10.1016/B978-0-12-800269-8.00011-7. PMID 25081084
  7. Rui X, Pan HF, Shao SL, Xu XM. Anti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway. BMC Complement Altern Med. 2017 Aug 1;17(1):378. doi: 10.1186/s12906-017-1885-y. PMID 28764703
  8. Lee H, Kim JS, Kim E. Fucoidan from seaweed Fucus vesiculosus inhibits migration and invasion of human lung cancer cell via PI3K-Akt-mTOR pathways. PLoS One. 2012;7(11):e50624. doi: 10.1371/journal.pone.0050624. PMID 23226337
  9. Han YS, Lee JH, Lee SH. Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. Mol Med Rep. 2015 Sep;12(3):3446-3452. doi: 10.3892/mmr.2015.3804. PMID 25998232